In search of sustainability: process R&D in light of current pharmaceutical industry challenges.

Is there a need for a paradigm shift in the pharmaceutical industry? Many researchers think so and take as examples the eroding corporate reputation, a regulatory environment that is harsher than ever, and the request for cheaper drugs from patient organizations and authorities. Process R&D, which interfaces medicinal chemistry and production, has taken on this challenge by increasing the delivery focus early on to ensure timely availability of desired compounds. The quest for lower costs of goods has forced the design of best synthetic routes that, given the molecular complexity, often lead to catalytic methodologies. Applying these methodologies will enable not only the cost element, but also the increasingly important aspects of environmental friendliness, and atom and stage efficiency, to be addressed.

[1]  B. Pugin,et al.  Progress in enantioselective catalysis assessed from an industrial point of view , 2005 .

[2]  Hans-Jürgen Federsel Stereoselective Synthesis of Drugs – An Industrial Perspective , 2006 .

[3]  S. LaPlante,et al.  RCM of tripeptide dienes containing a chiral vinylcyclopropane moiety: impact of different Ru-based catalysts on the stereochemical integrity of the macrocyclic products. , 2005, The Journal of organic chemistry.

[4]  Christian Wandrey,et al.  Industrial Biocatalysis: Past, Present, and Future , 2000 .

[5]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[6]  Fredric Cohen,et al.  Macro trends in pharmaceutical innovation , 2005, Nature Reviews Drug Discovery.

[7]  K. Prasad,et al.  The Art of Meeting Palladium Specifications in Active Pharmaceutical Ingredients Produced by Pd-Catalyzed Reactions , 2004 .

[8]  H -J. Federsel Drug discoverers -you need us! , 2001, Drug discovery today.

[9]  Hans-Jürgen Federsel,et al.  Asymmetry on large scale: the roadmap to stereoselective processes , 2005, Nature Reviews Drug Discovery.

[10]  Kurt Faber,et al.  Biotransformations in Organic Chemistry , 1992 .

[11]  P. Preziosi,et al.  Science, pharmacoeconomics and ethics in drug R&D: a sustainable future scenario? , 2004, Nature Reviews Drug Discovery.

[12]  Sean Ekins,et al.  Reengineering the pharmaceutical industry by crash-testing molecules. , 2005, Drug discovery today.

[13]  Andreas Vogel,et al.  Expanding the range of substrate acceptance of enzymes: combinatorial active-site saturation test. , 2005, Angewandte Chemie.

[14]  D. Ripin,et al.  Survey of GMP Bulk Reactions Run in a Research Facility between 1985 and 2002 , 2005 .

[15]  Simon Frantz 2005 approvals: Safety first , 2006, Nature Reviews Drug Discovery.

[16]  J. Bäckvall,et al.  Racemisation in asymmetric synthesis. Dynamic kinetic resolution and related processes in enzyme and metal catalysis , 2001 .

[17]  Bruce L. Booth,et al.  Opinion: Prospects for productivity , 2004, Nature Reviews Drug Discovery.

[18]  David J. Triggle,et al.  Medicines in the 21st century Or pills, politics, potions, and profits: Where is public policy? , 2003 .

[19]  Hans-Jürgen Federsel The role of process R&D in drug discovery: Evolution of an interface , 2004 .

[20]  Esther F. Schmid,et al.  Keynote review: Is declining innovation in the pharmaceutical industry a myth? , 2005, Drug discovery today.

[21]  Michael M. Ting,et al.  The political logic of regulatory error , 2005, Nature Reviews Drug Discovery.

[22]  W. Knowles Asymmetric hydrogenations (Nobel lecture). , 2002, Angewandte Chemie.

[23]  H -J. Federsel Drug discoverers - you need us! - Reply. , 2001, Drug discovery today.

[24]  B. D. Vineyard,et al.  Catalytic asymmetric hydrogenation , 1972 .

[25]  G. Rothenberg,et al.  Optimal Heck Cross‐Coupling Catalysis: A Pseudo‐Pharmaceutical Approach , 2003 .

[26]  John Andraos,et al.  Unification of Reaction Metrics for Green Chemistry: Applications to Reaction Analysis , 2005 .

[27]  Federsel Building bridges from process R&D: from a customer-supplier relationship to full partnership. , 2000, Pharmaceutical science & technology today.

[28]  John L. Tucker,et al.  Green Chemistry, a Pharmaceutical Perspective , 2006 .

[29]  E. Jacobsen,et al.  Practical Considerations in Kinetic Resolution Reactions , 2001 .

[30]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[31]  Barry M. Trost,et al.  Atom Economy—A Challenge for Organic Synthesis: Homogeneous Catalysis Leads the Way , 1995 .

[32]  Carl R. Johnson Biotransformations in the Synthesis of Enantiopure Bioactive Molecules , 1998 .

[33]  Hans-Jürgen Federsel Development of a Process for a Chiral Aminochroman Antidepressant: A Case Story† , 2000 .

[34]  P. Anastas,et al.  Green Chemistry , 2018, Environmental Science.

[35]  Hans-Jürgen Federsel,et al.  A guide to drug discovery: Logistics of process R&D: transforming laboratory methods to manufacturing scale , 2003, Nature Reviews Drug Discovery.

[36]  J. Mauskopf,et al.  A guide to drug discovery: Pricing medicines: theory and practice, challenges and opportunities , 2005, Nature Reviews Drug Discovery.

[37]  V. Gewin Chemistry's evolution , 2006 .

[38]  Merrill Goozner,et al.  The $800 Million Pill: The Truth behind the Cost of New Drugs , 2004 .

[39]  B. Trost,et al.  The atom economy--a search for synthetic efficiency. , 1991, Science.

[40]  Jimmy O. DaSilva,et al.  Adsorbent Screening for Metal Impurity Removal in Pharmaceutical Process Research , 2005 .

[41]  Hans-Ulrich Blaser,et al.  Enantioselective catalysis in fine chemicals production. , 2001, Chemical communications.

[42]  E. Antman Inside the FDA: The Business and Politics Behind the Drugs We Take and the Food We Eat , 2005 .

[43]  I. Alfonso,et al.  Enantioselective enzymatic desymmetrizations in organic synthesis. , 2005, Chemical reviews.

[44]  E. Jacobsen,et al.  Privileged Chiral Catalysts , 2003, Science.

[45]  Roxanne Khamsi Painkiller verdict shows mistrust of Merck , 2005, Nature.

[46]  Biological chemistry: Enzymes in focus , 2005, Nature.

[47]  John Potoski,et al.  Timely synthetic support for medicinal chemists. , 2005, Drug discovery today.

[48]  Hans-Jürgen Federsel The integration of process R&D in drug discovery--challenges and opportunities. , 2006, Combinatorial chemistry & high throughput screening.

[49]  Mark E. Davis,et al.  Catalysis for Environmentally Benign Processing , 1994 .

[50]  David F. Horrobin,et al.  Modern biomedical research: an internally self-consistent universe with little contact with medical reality? , 2003, Nature Reviews Drug Discovery.

[51]  B. Trost Asymmetric catalysis: an enabling science. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[52]  R. Sheldon Catalysis: The Key to Waste Minimization * , 1997 .

[53]  and Peter J. Harrington,et al.  Twenty Years of Naproxen Technology , 1997 .

[54]  Martin Poirier,et al.  Synthesis of BILN 2061, an HCV NS3 protease inhibitor with proven antiviral effect in humans. , 2004, Organic letters.

[55]  M. Dickson,et al.  Key factors in the rising cost of new drug discovery and development , 2004, Nature Reviews Drug Discovery.

[56]  Hans-Jürgen Federsel Start small, think big — the art of process R&D , 2002, Nature Reviews Drug Discovery.

[57]  M. Rawlins Cutting the cost of drug development? , 2004, Nature Reviews Drug Discovery.

[58]  V. Gotor Biocatalysis Applied to the Preparation of Pharmaceuticals , 2002 .

[59]  Carl M. Cohen A path to improved pharmaceutical productivity , 2003, Nature Reviews Drug Discovery.